Previous 10 | Next 10 |
home / stock / pfe / pfe articles
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and affo...
Around 15% of Americans said they were planning to participate this year in Dry January — a month of abstinence from alcohol — according to a s...
In a year when equity markets rallied strongly, short sellers — traders who position for losses on assets — had an extremely tough time in 2023...
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. as...
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies ar...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first...
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the ...
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 06:28:00 ET Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess ...
2024-07-01 10:48:00 ET It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago....
Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board. Mr. Taraporevala served as Presid...